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There is evidence from some countries of a trend towards increasingly aggressive pharmacological
treatment of patients with advanced, incurable cancer. To what extent should this be understood as a
progressive development in which technological innovations address previously unmet needs, or is a
signiﬁcant amount of this expansion explained by futile or even harmful treatment? In this article it is
argued that while some of this growth may be consistent with a progressive account of medicines
consumption, part of the expansion is constituted by the inappropriate and overly aggressive use of
drugs. Such use is often explained in terms of individual patient consumerism and/or factors to do with
physician behaviour. Whilst acknowledging the role of physicians and patients' expectations, this paper,
drawing on empirical research conducted in the US, the EU and the UK, examines the extent to which
upstream factors shape expectations and drive pharmaceuticalisation, and explores the value of this
concept as an analytical tool.
© 2014 The Author. Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction
Since themid-1990s, a number of studies have focused attention
on the growing importance of pharmaceuticals in our day-to-day
lives. This work has been reviewed by Abraham (2009, 2010) and
by Williams et al. (2011), and recent articles by these scholars and
by Busﬁeld (2010) from the United Kingdom (UK) have provided
broad overviews of the rapid expansion in medicines use over
recent decades, and suggested conceptual and heuristic frame-
works for the development of future sociological analyses.
Abraham and Williams et al. suggest that processes of ‘pharma-
ceuticalization’ e ‘[t]he transformation of human conditions, ca-
pacities or capabilities into opportunities for pharmaceutical
intervention’ (Williams et al., 2011, 711) e have driven this
expansion, and all authors agree that the trend cannot be
adequately explained by ‘progressive’ accounts of techno-scientiﬁc
progress meeting population health needs e what Abraham calls
the ‘biomedicalism thesis’ (2010, 606).
As Abraham argues, addressing the validity of biomedical ex-
planations is crucial to any analysis since it is directly relevant to
sociological understanding and evaluation of the impacts of phar-
maceuticalisation, including ‘the implications ofLtd. This is an open access articlepharmaceuticalization for health’ (Abraham, 2010, 606). Of the
three overviews, only Abraham attempts in any substantive way to
address the plausibility of what he calls the biomedicalism thesis as
an explanation for overall pharmaceutical expansion, arguing that,
given an overall decline in therapeutic innovation since the late
1990s, ‘biomedicalism… cannot be an explanation for the growth in
overall pharmaceutical markets or expanded pharmaceuticalization
in some therapeutic areas, because no such growth or expansion of
drug innovation offering signiﬁcant therapeutic advance has
occurred in the last 15e20 years’ (2010, 616). However, this argu-
ment is problematic in that it fails to recognise that increased rates
of medicines prescribing can also be explained by increased uti-
lisation of existing drugs to meet the established health needs of a
growing patient population, despite declining rates of therapeutic
innovation. Patient populations may expand due to demographic
factors, higher incidence rates of disease, and/or improved diag-
nosis or access to healthcare. In such cases, biomedical explana-
tions may provide a sufﬁcient explanation for higher rates of
medicines utilisation. More detailed analyses of patterns of use, the
plausibility of different explanatory factors, and the impacts of
increased medicines consumption within speciﬁc disease areas is
needed to test ‘progressive’ explanations and shed further light on
the usefulness of ‘pharmaceuticalization’ as a conceptual tool.
This article explores the drivers and impacts of expanding
medicines use in the treatment of patients with advanced,under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
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draws on research, undertaken between 2008 and 2013, investi-
gating the dynamics of patient advocacy and the regulation of new
anticancer drugs. This research involved extensive documentary
data collection and analysis, including review of the scientiﬁc, so-
cial scientiﬁc and ‘grey’ literature. Fieldwork was undertaken in the
United States (US), the UK and throughout the European Union
(EU), and a total of 60 semi-structured interviews were conducted
with a purposive sample of: US cancer patient advocates and ad-
vocates acting at the level of the supranational EU (representing 41
separate patient groups and 13 tumour types); medicines regula-
tors; cancer specialists; journalists and other stakeholders. Ethics
approval was obtained for the research and participants gave
informed consent before taking part. In-depth interview guides
covered a range of topics including respondents' perceptions of the
therapeutic value of new drugs, patients' interests and needs, at-
titudes towards regulatory science and standards, the balance be-
tween evidence development and access to newmedicines, patient
and public participation in medicines regulation and new drug
development, and the nature of relationships between the different
stakeholders. Data was analysed against an initial coding frame
reﬂecting the central research questions of the project and relevant
data falling outside the initial frame was used to modify the coding
iteratively, until no more useful information could be extracted.
To interrogate the plausibility of progressive accounts of medi-
cines expansion in the treatment of patients with advanced met-
astatic solid tumours, this paper begins with a review of the
scientiﬁc literature, including recent assessments of the clinical
beneﬁts offered by new anticancer drugs, an evaluation of these
beneﬁts in the context of studies of patient expectations and
preferences, and a review of research investigating the impacts of
chemotherapeutic expansion towards the end-of-life. I argue that,
taken as a whole, this evidence raises signiﬁcant doubts about the
credibility of biomedical explanations for the increased utilisation
of chemotherapy in patients with end-stage disease. I then utilise
William et al.'s (2011) concept of a ‘pharmaceutical regime’ e and
the shifting conﬁguration of relationships between key actors and
institutions e to explore alternative explanations for this chemo-
therapeutic expansion. Finally, I consider the usefulness of ‘phar-
maceuticalisation’ as a lens through which to view these dynamics.
2. Chemotherapeutic expansion: a model of progress?
There is a lack of comprehensive and publicly accessible data on
long-term, national-level trends in oncology drug prescribing.
However, available data indicates that utilisation has indeed
increased. According to US pharmacy beneﬁts data analysed by
Express Scripts there was a 3.4% increase in utilisation of cancer
drugs between 2011 and 2012, and a 10.5% increase between 2012
and 2013 (Express Scripts, 2013, 2014). In the UK, data from one
large cancer network show that between 2003/04 and 2009/10
there was a 67% increase in the number of chemotherapy courses
given to cancer patients with solid tumours (Roche et al., 2010) and
comprehensive, national-level data from France also demonstrates
expanding utilisation of chemotherapy. Between 2005 and 2010,
the number of patients receiving chemotherapy grew by 20% e
faster than the growth in the number of new cancer patients
diagnosed (INCa, 2012, 10). Finally, large population-based studies
provide evidence of a temporal trend of increasing use of chemo-
therapy towards the end-of-life in North America (Earle et al., 2004,
2008; Ho et al., 2011), and the Netherlands (Bernards et al., 2013).
On ﬁrst inspection, the plausibility of the biomedical thesis in
accounting for this growth appears high. Globally, both the inci-
dence and prevalence of cancer are increasing (WHO, 2013). In
addition, many cancers continue to carry a poor prognosis andalmost 50% of cancer patients will eventually develop metastatic
disease (Koedoot et al., 2003), hence there is a desperate need for
more effective treatments. Has this growing demand beenmatched
by increased availability of effective new therapies? Here again, the
indicators appear to support a progressive account of chemother-
apeutic expansion. Oncology has become a major area for R&D
investment by the biopharmaceutical industry over the last two
decades, and this has resulted in a 70% increase in the number of
drugs available to treat cancer in 2005 compared with 1995
(Analysis Group, 2013; Jonsson and Wilking, 2007). Furthermore,
evaluations by medicines regulators in the US and EU indicate that
between a third and one half of all newapproved cancer indications
offer important therapeutic advances over existing treatment op-
tions (Davis and Abraham, 2013, 155e157; Sherman et al., 2013).
This would have the effect of both expanding the ‘treatable’ patient
population and of increasing the number of drugs prescribed per
patient, since new drugs are often used in combination with
established therapies for various stages of the disease (Niraula
et al., 2012; INCa, 2012, 10).
For patients with metastatic cancer, the current clinical research
paradigmmeans that most new drugs are ﬁrst tested and approved
for use in patients with advanced disease who have exhausted
existing treatment options (Goss et al., 2012). This may have
resulted in expanded utilisation, and increased duration of
chemotherapy use towards the end-of-life (Martoni et al., 2007,
420; Murillo and Koeller, 2006; Temel et al., 2008, 830; see also
below). According to the industry, regulatory agencies and some
research scientists and patient advocates, this ‘pharmaceuticalisa-
tion’ in the treatment of advanced cancer represents a gain for in-
dividuals and society as more patients are able to beneﬁt from the
therapeutic advances offered by these new treatments in terms of
life-extension and improved quality of life (Goss et al., 2012). Yet
there is accumulating evidence that whilst increasing numbers of
patients with advanced disease receive drug treatment, the bene-
ﬁts offered by new drugs may not match patients' expectations or
informed preferences and that aggressive use of chemotherapy
towards the end-of-life is associated with poorer quality of life and
death, regret, ﬁnancial hardship and possibly shorter survival. This
evidence and related issues are considered below.
3. What patients need and want (and what they get)
Since most metastatic solid tumours are incurable, the goal of
chemotherapy for patients must be ‘palliative’ e that is, drug
treatment should relieve disease-related symptoms, improve
quality of life or prolong life without an unacceptable impact on
quality (Braga, 2011; Doyle et al., 2001). Clinicians refer to care as
‘futile’ when patients are administered burdensome, toxic and
potentially life threatening therapies that will not achieve any of
these goals (von Gruenigen and Daly, 2005). A decision to forgo
‘disease-directed’ chemotherapy e that is, chemotherapy aimed at
shrinking or stabilising the tumour e does not entail ‘doing
nothing’ for patients. Instead, ‘palliative’ or hospice care focuses on
relief of pain and other symptoms, and on enhancing patients'
general physical, psychosocial and spiritual wellbeing (Rocque and
Cleary, 2013). Whilst anticancer drugs may have a role to play in
treating patients near the end-of-life, by deﬁnition, palliative care
should not include anticancer drugs that could negatively impact
on quality-of-life. The more marginal or uncertain the degree of
beneﬁt offered by drug therapy, the less likely it will be that the
risk-beneﬁt balance of drug treatment will be positive since all
pharmaceutical use carries some risk.
Given evidence of chemotherapeutic expansion amongst pa-
tients with advanced disease, it is therefore particularly concerning
that a number of recent, independent reviews indicate that the
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at best marginal and often uncertain (Fojo et al., 2014; Garattini and
Bertele, 2002; Kantarjian et al., 2013; Ocana and Tannock, 2011).
Whilst it is true that a few, new anticancer drugs have genuinely
changed disease prognosis and standards of care, most new drugs
for advanced cancer are not in this camp (Fojo and Parkinon, 2010,
5972). For example, Sobrero and Bruzzi (2009) found that the
median overall survival gain offered by new biologics over existing
treatments in advanced disease was just 2 months. And with
respect to the widespread belief that the new, targeted therapies
are relatively non-toxic, Niraula et al. (2012) found that these
agents are more likely to cause serious (grade 3e4) toxicities when
administered as monotherapy or as an ‘add-on’ to standard
chemotherapy regimens, and are also more likely to cause treat-
ment discontinuation and toxic death when combined with exist-
ing regimens.
These analyses convey a very different picture to the US Food
and Drug Administration's (FDA's) estimation that over half of all
new oncology indications approved between 2010 and 2012
represent important advances in safety or effectiveness. If the
beneﬁts of new drugs are marginal for the majority of patients, and
toxicity sometimes severe, then the risk-beneﬁt calculation for
using these drugs near the end-of-life is unlikely to be positive. This
is particularly true since patients in ‘the real world’ are generally
sicker, and less likely to respond positively to treatment, than pa-
tients enrolled in clinical trials (Schnipper et al., 2012; Unger et al.,
2014).
There are two frequent responses to an observation that the
survival gains offered by new drugs are small. First, it is sometimes
claimed that the additive impact of these incremental gains may be
to keep individual patients alive for signiﬁcant periods of time. For
example, some expert clinicians have claimed that in metastatic
kidney cancer, the availability of Sutent and other targeted thera-
pies has extended the average survival rate from 14 months to
somewhere in the range of 36e48 months and that, ‘[t]argeted
drugs are driving [improvements in cancer] survival in amajor way’
(Wells and Pettypiece, 2010). However, recent population-based
studies directly undermine such claims and show that new anti-
cancer agents have not signiﬁcantly improved cancer survival rates
beyond 2e3months (Bernards et al., 2013; Renouf et al., 2011; Saito
et al., 2011; Shah and Ghimire, 2013).
Second, it is frequently asserted that cancer patients with
advanced disease and short life-expectancy are willing to accept
considerable toxicity for a small chance of beneﬁt (Matsuyama
et al., 2006, 3493). Here again, however, published research does
not necessarily support the accepted wisdom (Mack et al., 2010).
Most studies show that patients' expectations of drug therapy
greatly exceed the beneﬁts actually offered (Donovan et al., 2002;
Mende et al., 2013; Silverstri et al., 1998; although see Wright
et al., 2014), and that between one-third and four-ﬁfths of pa-
tients with advanced cancer mistakenly believed that palliative
chemotherapy might cure their disease (Doyle et al., 2001; Temel
et al., 2011; Weeks et al., 2012). Widespread overestimation of
the beneﬁts of chemotherapy appears to inﬂuence some patients'
choice to undergo treatment. For example, in a study of 134 pa-
tients with metastatic disease who had already received a median
of 6-months of chemotherapy, Mende et al. (2013) found that 88%
stated they would undergo treatment again. However, when asked
to specify the minimum survival gain necessary for them to repeat
therapy, study participants' median thresholds for survival were 18
months for non-colorectal cancer patients and 36 months for
colorectal cancer patients. So while the majority of patients in this
study would repeat chemotherapy, this was based on expected
beneﬁts that far exceed the actual survival gains offered by anti-
cancer agents in the metastatic disease setting.4. Treating patients near the end-of-life: knowing when to
stop
As previously discussed, there is a lack of publicly available,
comprehensive data on trends in chemotherapy use. However, in
response to concerns that some patients with metastatic solid tu-
mours may be overtreated with chemotherapy, a number of recent
studies have investigated the extent of chemotherapy use in pa-
tients with advanced cancer. Despite considerable variation be-
tween institutions and regions, a number of studies have found
high rates of utilisation near the end-of-life in both the US and the
EU, along with other indicators of overuse such as administration of
drugs to patients with poor performance status, chemo-insensitive
tumours and several previous lines of chemotherapy (Braga et al.,
2007; Colombet et al., 2012; Earle et al., 2004; Emanuel et al.,
2003; Martoni et al., 2007; Murillo and Koeller, 2006; Nappa
et al., 2011; Schnipper et al., 2012; Temel et al., 2008; von
Gruenigen et al., 2008).
Evidence of intensive chemotherapy use near the end-of-life is
not, in itself, evidence of harm. However, a number of these studies
have also demonstrated that compared to patients not receiving
drug treatment close to death, such treatment is associated with
poorer quality of life and death e for example, a higher number of
emergency room visits and admissions to ICU, fewer hospice ser-
vices, decreased likelihood of patients dying in their preferred
place, increased physical and psychological distress and, in some
countries, bankruptcy (Earle et al., 2004; Greer et al., 2011; Mack
et al., 2010; Temel et al., 2010; Wright et al., 2014; Zafar et al.,
2013). Moreover, patients receiving chemotherapy near the end-
of-life do not live longer than patients not receiving such therapy
(Nappa et al., 2011; Saito et al., 2011; von Gruenigen et al., 2008). On
the contrary, in one recent randomized study less use of intravenous
chemotherapy was strongly associated with increased survival
(Greer et al., 2011).
Taken as a whole, this evidence suggests that aggressive end-of-
life care occurs in a signiﬁcant proportion of patients in the EU and
the US, is associated with poorer quality of life and death, and
possibly reduced survival. Moreover, research investigating cancer
patients' expectations of chemotherapy raises the possibility that a
substantial number of patients with metastatic disease would not
choose to continue drug treatment if they were genuinely made
aware of its limited, or uncertain, beneﬁts.
5. Understanding trends in drug treatment: the gap between
rhetoric and reality
Rates of drug administration near the end-of-life vary between
countries and between institutions. For example, the proportion of
patients receiving chemotherapy in their ﬁnal month of life in the
EU ranged from 8% in one UK institution (O'Brien et al., 2006), up to
37% in a Portuguese hospital (Braga et al., 2007). Clearly, differences
in national culture, the organisation and funding of healthcare e
including the existence of perverse ﬁnancial incentives (Keating
et al., 2010) e and institutional practice are factors that will inﬂu-
ence trends in chemotherapeutic expansion and possible overuse
of drugs. However many EU studies found rates of utilization in the
last 30 days of life that approachede and in some cases exceedede
those in the US, despite diverse healthcare systems and the absence
of US-type ﬁnancial incentives to prescribe chemotherapy. Dis-
cussions of overtreatment and futile end-of-life care in the medical
literature have tended to explain these phenomena in terms of
either individual physician and patient psychology, or professional
culture and training (Braga, 2011; Earle, 2011; Harrington and
Smith, 2008; Mack and Smith, 2012). However, these phenomena
cannot explain evidence of a temporal trend of increasingly
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growing recognition of the importance of palliative end-of-life care
and an expansion in the provision of palliative and hospice services.
One factor underlying the trend has been the rapid growth in
the availability of drugs to treat metastatic cancer since the mid-
1990s. In addition to expanded treatment options, a number of
commentators have pointed to increasing pressure from patients or
families as factors driving potentially futile initiation/continuation
of chemotherapy (Morita et al., 2004), and recent sociological work
has focused on ‘the rise of the articulate or information rich con-
sumer’ of healthcare (Williams et al., 2011, 717). However, whilst an
expanded armamentarium and growing consumerism may be
proximal factors inﬂuencing recent trends, neither can adequately
account for current medical practice since most new drugs offer
marginal beneﬁts which do not, according to available evidence,
meet the majority of patients' informed preferences for, or expec-
tations of treatment.
To understand this gap between expectations and reality we
need to identify, on the one hand, key features of the current
‘pharmaceutical regime’ (Williams et al., 2011) in oncology which
determine the kind of drugs we get and, on the other, the forces
that are shaping patient and physician expectations. As social sci-
entists have repeatedly demonstrated, medicines availability and
use are the outcome of numerous complex and interrelated social,
economic, and political (as well as techno-scientiﬁc) factors that
determine how they are tested, governed, marketed and consumed.
Industry, regulators, professional bodies, medical journals, the
research community, expert clinicians, patient groups and the
media play variously important roles in shaping the production and
consumption of new drugs. The following sections provide an
overview of some of these dynamics.
5.1. The industry-research-regulatory nexus
Industry is now the main funder of randomized controlled trials
(RCTs) in oncology and this means that companies' commercial
interests are the key inﬂuence in determining the objectives and
design of trials (Booth, 2010). Companies seek tomarket their drugs
andmaximise proﬁts for shareholders and investors, but in order to
do this they must ﬁrst demonstrate to national and supranational
drug regulatory authorities that their products meet current stan-
dards of safety and efﬁcacy. Increasingly, companies are also
required to demonstrate the cost-effectiveness of their products to
national health technology assessment and reimbursement bodies.
Unfortunately, current standards for market approval in the US and
the EU fail to ensure that new anticancer therapies offer clinically
meaningful beneﬁts patients.
First, any statistically signiﬁcant difference in overall survival,
however small, has been accepted as a basis for approving new
drugs (Pazdur, 2008). Second, since the mid-1990s, regulators in
the US and EU have further lowered the regulatory bar by intro-
ducing accelerated/conditional approval mechanisms that allow
new cancer drugs to be tested against ‘non-validated surrogate
endpoints’ (Davis and Abraham, 2011, 2013, 158). These surrogate
endpoints e such as ‘progression-free survival’ and tumour
shrinkage e are radiological measurements that demonstrate a
drug has biological activity, but do not reliably predict whether it
will improve the outcomes that really matter to patients e namely
survival, symptom-control, functioning and/or quality of life (Amir
et al., 2012; Booth, 2010; Booth and Eisenhauer, 2012; Fallowﬁeld
and Fleissig, 2012; Gutman et al., 2013; Salz, 2009). Permissive
regulatory standards encourage companies to construct their
business models and drug development programmes around small,
incremental gains that create considerable uncertainty for patients,
clinicians and healthcare payers regarding the true clinical value ofnew oncology drugs (Davis and Abraham, 2013; Fojo et al., 2014;
Ocana and Tannock, 2011).
The political history and neoliberal corporate bias underlying
these ‘reforms’ is described in some detail by Davis and Abraham
(2013). Brieﬂy, while changes to regulatory standards and
approval mechanisms were justiﬁed on the grounds they would
speed important new therapies to patients, they were in fact
implemented by regulatory authorities under pressure from the US
Congress and EU Commission, which were in turn driven by a
determination to boost the relative economic competitiveness of
their life sciences industries within the global economy (Davis and
Abraham, 2011, 2013).
The current elevation of ‘international competitiveness’ by na-
tional and supranational governments as a (or perhaps ‘the’) pri-
mary concern for state policy may also be transforming the
orientation of publicly-funded research in ways that are not in the
best interests of patients or public health. There is evidence that
public funding bodies, as well as the largest philanthropic funders,
are concentrating resources on research to support drug discovery
and development to the neglect of other types of investigation
(European Commission, 2007; FDA, 2004; Kanavos et al., 2010). One
consequence of these shifts is that it is increasingly difﬁcult for
researchers to attract funding for applied clinical research ques-
tions that do not involve drugs (Braga, 2011, 2347). This means
there may now be a very poor correspondence between both public
and private-sector research priorities and the actual concerns and
information needs of patients and clinicians. For example, accord-
ing to a study inwhich cancer patients in the UKwere asked to rank
their research priorities, participants were more likely to prioritise
research on psychosocial issues e such as the impact of disease,
how to live with it and other support issues e than research on
anticancer treatments (Corner et al., 2007).
5.2. The oncology community
The role of the wider oncology community in supporting
particular patterns of drug production and consumption in
advanced cancer is mixed. On the one hand, the general culture of
cancer therapy has historically been characterised by an aggressive
and experimental approach to treatment (Mello and Brennan,
2001; Mukherjee, 2011) and oncologists have embraced (possibly
meaningless) increments in survival (Fojo and Grady, 2009; Sacher
et al., 2014). Moreover, despite acknowledgement by the oncology
community of the potential for overtreatment near the end-of-life,
existing guidelines from professional bodies do not specify a clear
timeframe for stopping drug treatment (NCCN, 2013), and an
American Society of Clinical Oncology (ASCO) panel reporting in
1996 could not decide on a minimal beneﬁt for which chemo-
therapy was indicated, only that some proven beneﬁt must be
demonstrable (Swetz and Smith, 2010, 468).
On the other hand, some prominent clinicians have begun to
focus attention on the high costs and low beneﬁts of new cancer
drugs (Bach et al., 2012; Fojo and Grady, 2009; Fojo and Parkinon,
2010; Fojo et al., 2014; Garattini and Bertele, 2002; Hall, 2013;
Kantarjian et al., 2013; Niraula et al., 2012; Salz, 2009; Schrag,
2004; Seruga et al., 2010; Sobrero and Bruzzi, 2009; Sullivan
et al., 2011; Zafar et al., 2013). This public questioning of the sky-
rocketing costs and underwhelming performance of new oncology
treatments has been powerful enough to push ASCO to propose
minimal efﬁcacy thresholds for pancreatic, lung, breast and colo-
rectal cancer (Ellis et al., 2014). However, there is by no means a
consensus within the community on these issues (Berger et al.,
2010; Johnson, 2014), and since companies have ultimate control
over the design of the majority of clinical trials it is uncertain
whether this push fromwithin the professional community will be
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neously raising standards for market approval.
The patient advocacy community has also been divided over
issues of evidence, clinical value and regulatory standards. In the
US, considerable disagreement exists between, on the one hand,
advocates who believe current regulatory standards for the mar-
keting of new cancer therapies are too high (acting as a barrier to
both patient access and industry investment in future research)
and, on the other hand, advocates who believe the standards are
too low, and fail to stimulate research and development of new
drugs that offer genuine therapeutic advance (Mayer, 2003; Mayer,
2010; Trowbridge and Walker, 2007).
Most patient groups rely on companies to keep them informed
about new drugs in clinical trials or under regulatory review (US
Patient Advocate B, 2010; US Patient Advocate E, 2011; UK Patient
Advocate A, 2011; EU Patient Advocate A, 2012). But over-
dependence on industry-generated data, and lack of access to
alternative sources of information, means advocates may be easily
persuaded to endorse a particular drug or lobby regulators for
marketing approval (US Patient Advocate F, 2011), and companies
may use groups to manufacture what one prominent breast cancer
advocate has called ‘access advocacy’ (Mayer, 2003) where advo-
cates pressure regulators to allow drugs to bemarketed on the basis
of an incomplete evidence base. Companies have also attempted to
partner with groups to set up pre-marketing ‘expanded access
programmes’ (EAPs) e programmes through which patients who
are not eligible for clinical trials may nevertheless access an
investigational producte as away of generating support within the
patient community for their drugs. EAPs, ‘access advocacy’ and
patient endorsements provide companies with a means of gener-
ating expectations in the pre-marketing period and signal to in-
vestors, patients and physicians that their drug is important to
patients (US Patient Advocate D, 2011; US Patient Advocate F, 2011).
In countries with publicly funded healthcare systems, ‘access
advocacy’ has tended to be directed at reimbursement decision-
makers (Abraham, 2009, 963e964; Booth et al., 2007; Busﬁeld,
2010, 939; Gabe et al., 2012).
Even when patient advocates are aware that a new drug offers
marginal beneﬁts, there are a number of reasons why they may be
reluctant to publicly question the value of new anticancer thera-
pies. First, some patients are genuinely willing to accept a very
small chance of beneﬁt from drug therapy and advocates feel it is
their job to represent those patients' interests (UK Patient Advocate
B, 2011). Advocates may also believe that patients need ‘hope’, and
this belief disinclines many advocates from publicly drawing
attention to the gap that can exist between rhetoric and reality (US
Patient Advocate C, 2011; UK Patient Advocate C, 2012). Second,
some advocates e particularly those representing patients for
whom there are few, or no, good therapeutic options e value new
drugs as important (albeit incremental) ‘stepping stones’ that may
lead eventually to genuine breakthroughs. And advocates have
described occasions when industry representatives explicitly told
them that companies would not continue to develop new drugs for
a speciﬁc condition if the regulatory hurdles were too high (UK
Patient Advocate B, 2011). Finally, there is a real risk that com-
panies will withdraw ﬁnancial support from critical groups, and the
reliance of many advocacy organisations on industry funding may
contribute to an advocacy community that is unwilling to ask hard
questions about new drugs (US Patient Advocate A, 2009). One
advocate, for example, described how her group lost funding from
two sponsors when she publicly challenged the safety of their
products (US Patient Advocate D, 2011).5.3. Hype and hope: (mis)representing the beneﬁts of new drugs
In contrast to the small, incremental gains pursued by com-
panies and sanctioned by regulators, many patients have expecta-
tions of chemotherapy far beyond the beneﬁts that current drug
treatments actually offer. One reason for this mismatch is doctors'
failure to communicate honestly with patients about the real value
of drug treatment (Mack and Smith, 2012), but the problem extends
beyond micro-sociological factors. Within the wider ‘information
landscape’ for patients, clinicians and the public, the marginal or
uncertain beneﬁts of new anticancer therapies are transformed by
the alchemy of positive spin and hopeful reportage into ‘magic
bullets’ and ‘miracle drugs’ (Wells and Pettypiece, 2010). Much of
the information landscape is shaped by industry, but expert clini-
cians, research organisations, regulators, patient groups and the
media play their part.
Recent studies show that unbalanced news media reporting,
which exaggerates the beneﬁts of new anticancer drugs, is the
norm (Fishman et al., 2010; Hind et al., 2011) and that general
reporting of cancer research overemphasises drug therapy to the
exclusion of other therapeutic modalities (Lewison et al., 2008).
Press releases issued by companies frequently include glowing
endorsements by patient advocates and senior consultants despite
minimal gains, and the news media is quick to pick up on these
stories. For example, an item in the Daily Mail, following approval of
Zaltrap for metastatic colorectal cancer, carried a claim by the UK
patient group, Beating Bowel Cancer, that availability of the drug e
which improved survival by 6 weeks compared to placebo e was
‘excellent news’ for patients. Further quotes include statements by
senior medical oncologists that Zaltrap is ‘well tolerated’, and ‘has
the potential to signiﬁcantly impact survival rates in the future’
(Hope, 2013). Similarly, a US patient advocacy group, Colon Cancer
Alliance, reported on its website that recent approvals of Zaltrap
and another drug, marked ‘a milestone in the treatment of colon
cancer’ (Colon Cancer Alliance, undated). In contrast to these public
pronouncements, an experienced and knowledgeable patient
advocate in the US privately stated that Zaltrap was associated with
serious (grades 3e4) toxicities and did not represent a meaningful
advance for patients (US Patient Advocate D, 2011).
Regulators also generate unrealistic expectations, both in rela-
tion to the current beneﬁts offered by new therapies and in relation
to the promise of future advances. For example, the Commissioner
of the FDA recently proclaimed that, ‘America is at an important
crossroads, where the science before us presents unprecedented
opportunities to create new and better medical products and to
promote better health for the public’ (FDA, 2011). In a similar vein,
though with slightly less fanfare, a senior FDA scientist reassured
the public that the new anticancer drugs under agency reviewwere
‘slam dunks. It's not if we're going to approve them. It's how fast
we're going to approve them’ (Harper, 2013).
As well as exaggerating the beneﬁts of new drug treatments,
public discourse about cancer research is overwhelmingly positive
and hopeful. Cancer is the ‘poster child’ for scientiﬁc advances in the
molecular understanding of disease, and is constantly cited as the
ﬁeld in which the promise of personalised medicine is closest to
being realized (Schilsky, 2010). This hopeful reporting of the state of
cancer research and medicines originates from individual re-
searchers, and non-proﬁt and for-proﬁt institutions alike (Anon,
2000, 157), and may explain why the majority of people believe
that a cure for cancer will either ‘deﬁnitely’ or ‘probably’ be found
within 50 years (Anon, 2010).
Rarely does the public get to hear beyond the drumbeat of
medical progress. Even when patients and clinicians turn to the
scientiﬁc literature for reliable information, theymay still bemisled
over the value of new anticancer therapies. New drugs for non-
C. Davis / Social Science & Medicine 131 (2015) 207e214212small-cell lung cancer (NSCLC) offering an additional 5 weeks of
survival were reported in ASCO press brieﬁngs as drugs ‘likely to
have a signiﬁcant impact on the care of patients’ (Fojo and
Parkinon, 2010, 5973). As with other therapeutic areas, numerous
analyses have found evidence of biased and incomplete reporting of
trial results in the scientiﬁc and promotional literature (Altwairgi
et al., 2012; Rasmussen et al., 2009; Vera-Badillo et al., 2013;
Wick et al., 2007), and the ‘positive’ interpretation of oncology
trials has increased, along with the misreporting of trial results,
over the period inwhich industry replaced government as the main
funder of research (Booth, 2010; Sacher et al., 2014). Publication
bias, distorted scientiﬁc reporting, promotional material, and
stories of ‘miracle’ drugs percolate against a background discourse
of ‘science at a crossroads’ and ‘new eras’.
6. Conclusion
This article explores trends in chemotherapeutic expansion
amongst patients with advanced, metastatic solid tumours. While
some of this growth can undoubtedly be explained by an account of
medicines consumption in which pharmacological progress and
improved care meet expanding health needs e there is also evi-
dence of inappropriate and overly aggressive use of drugs. This
evidence demonstrates that although an increasing number of
patients with advanced disease receive drug treatment, this treat-
ment may not match their subjective expectations or informed
preferences and that, irrespective of patient preferences, aggressive
chemotherapeutic treatment towards the end-of-life is associated
with poorer quality of life and death, shorter survival, regret, and in
some cases severe ﬁnancial hardship.
Studies in the medical and psychological literature have
attempted to account for over-use in terms of individual patient
and physician behaviour and psychology. By situating chemother-
apeutic expansion within the conceptual framework of a wider
‘pharmaceutical regime’ we are able to trace the broader cultural,
political and institutional inﬂuences on patterns of drug production
and consumption. This analysis conﬁrms the pivotal roles played by
governments, the medical and research communities, regulatory
bodies, patient groups, and the media (Abraham, 2009, 2010;
Busﬁeld, 2010; Williams et al., 2011). Further, it shows that phar-
maceutical companies' control over the organisation and funding of
research, it's ability to shape the information landscape, and the
prioritisation of industry interests within regulatory agencies and
at the political level more broadly may entail negative conse-
quences for patients, public health and society as a whole.
First, excessive hype surrounding new anticancer therapies
creates a gap between what patients and the public expect from
drug therapy and what current regulatory standards, research,
treatment norms and industry business models deliver. This has
helped to fuel chemotherapeutic expansion and overtreatment of
patients near the end-of-life, with its attendant risks of physical,
psychological and ﬁnancial harm. Second, given the marginal or
uncertain beneﬁts of many new anticancer drugs, signiﬁcant soci-
etal resources have been (and continue to be) expended on
research and healthcare in a way that may be suboptimal for cur-
rent and future patients' health (Fojo et al., 2014). Third, current
regimes for funding clinical research have generated an excessive
focus on pharmacotherapy in the care of cancer that may increas-
ingly crowd out the pursuit and funding of research and healthcare
options not involving drugs (Braga, 2011; Kanavos et al., 2010;
Lewison et al., 2008) e an example, perhaps, of the colonisation
of health futures referred to byWilliams et al. (2011, 719e729). This
is not to say that patients do not beneﬁt from and value drug
treatments, or to deny that there is a real and urgent need for
genuine therapeutic breakthroughs that will signiﬁcantly improvehealth outcomes. It is simply to acknowledge that patients have
psychosocial, health, and support needs (including the need to
come to terms with death) which go beyond and sometimes
outweigh the need for new anticancer treatments (Corner et al.,
2007; Fallowﬁeld and Jenkins, 2013).
Whilst conﬁrming the value of an analytic framework that ex-
plores the relationships between multiple upstream and down-
stream factors in the production and consumption of anticancer
drugs, there are nevertheless issues raised by this case study that
are not adequately addressed by the concept of pharmaceuticali-
zation as currently deﬁned and which point, I believe, to the need
for further clariﬁcation and justiﬁcation of pharmaceuticalization's
conceptual boundaries.
Both Abraham (2009, 604e5), and Williams et al. (2011,
710e11), imply that the process of pharmaceuticalization involves
some re-designation of a condition as one suitable for pharmaceu-
tical intervention with new or existing drugs. It could be argued
that the documented trend towards increasingly aggressive and
late treatment of cancer patients near the end-of-life falls within
this deﬁnition. But there are instances of increased chemothera-
peutic consumption that are not obviously cases of pharmaceutic-
alization since they involve stages of the disease that were already
deemed suitable for drug treatment. For example, new drug
treatments are often added to an existing regimen of one to two
chemotherapy agents, which generally also adds to the toxicity of
treatment (Niraula et al., 2012). Such an expansion inmedicines use
is the product of the same ‘socio-technical regime’ (Williams et al.,
2011) and may carry similar consequences for patients and society,
so it is unclear why the former would be conceptualised as ‘phar-
maceuticalisation’, but not the latter.
We might resolve this issue by suggesting that ‘pharmaceutic-
alisation studies’ should encompass any instance of medicines
expansion (or decline) in use. Yet here again, there does not appear
to be a clear intellectual justiﬁcation for privileging a focus on cases
involving increasing/decreasing medicines production and con-
sumption, particularly if, as social scientists, we are interested in
evaluating both the ‘normative raison d'etre’ of healthcare and the
implications of medicines use for patient and public health
(Timmermans and Haas, 2008). For example, aggressive industry
marketing tactics that result in the substitution of new, more
expensive (but possibly less effective and more toxic) drugs for
cheaper generics is as important to understand and document as
disease-mongering or off-label use (Gale, 2001; Hill et al., 2008;
Light, 2010, 12e13). Such practices may or may not lead to an in-
crease in the number of pills consumed per head of population, but
they can still fuel the inappropriate and harmful utilisation of
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